Huawei Technologies Co., Limited

Weishang (shanghai) Bio-pharmaceutical Co., Ltd.

Chinese Academy of Fishery Sciences

Shenzhen Yuto Packaging Technology Co., Ltd

Wayshine Biopharm Holding Limited

Wei Zhong

Fan Zhang

Xiaoxiao Chen

Lei Zhang

Jun Zhu

Dao Pan

Yu Song

Peng Xiao

Zhang Gao

Qichao Yang

Jinqiang Zhang

Duoxian Li

Yequn Jiang

Bo Tang

Yingshi Xu

Tong Jiao

Letian Liu

Longjiao Xin

Fang Xia

Xi Lan

Haitao Gu

Liyu Liao

Zhaohui Yu

A quinazoline derivative (represented by the formula (I)) salt's crystal form, a preparation method and application are provided; specifically, the hydrochloride crystal form A, B, C, D, F, H, I, Sulphate crystal form A, Maleate crystal form A, Succinate crystal form A, Adipate crystal form A, Glycolate crystal form A, Malate crystal form A, Fumarate Salt crystal form A, besylate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and oxalate crystal form A of the quinazoline derivative represented by formula (I). The salt crystal form provided by the present invention has good stability, which can be used in the treatment of non-small cell lung cancer brain metastasis, meningeal metastasis, primary brain cancer or glioma, etc., and has good bioavailability, which is of great significance for further research on the efficacy of such solid drugs.

Quinazoline derivative salt crystal form, preparation method and application

An application interface layout method includes that a developer sets a layout container having an adaptive layout capability in a layout file of an application, where the adaptive layout capability includes at least one of an extension capability, a proportion capability, an equalization capability, a wrapping capability, a hiding capability, a stretching capability, or a scaling capability. In this way, when running the application, an electronic device arranges, based on a screen parameter of the electronic device and the adaptive layout capability of the layout container in the layout file, a size and a location of a child view in the layout container on a display interface.

Application interface layout method and electronic device

The present disclosure relates to a composite membrane and a packaging structure. The composite membrane comprises: a carrier layer; and an information layer, wherein the information layer is disposed on one side of the carrier layer along thickness direction of the composite membrane, and the information layer further comprises a light-transmitting layer, a first pattern layer, and a second pattern layer, which are disposed along the thickness direction of the composite membrane, wherein: the first pattern layer is disposed close to the carrier layer; the light-transmitting layer is disposed on one side of the first pattern facing layer away from the carrier layer; the second pattern layer is disposed on one side of the light-transmitting layer facing away from the carrier layer, and the second pattern layer and the first pattern layer present different visual information of one multi-dimensional object.

Composite membrane and packaging structure

A PLC control method includes: transmit a first signal through a neutral wire and a path between the neutral wire and a differential signal processing circuit; transmit a second signal through a live wire and a path between the live wire and the differential signal processing circuit; and disconnecting the path between the differential signal processing circuit and the neutral wire or the live wire, conducting the differential signal processing circuit to a ground wire, and when a transmission rate of the ground wire is greater than or equal to a preset transmission rate threshold, transmitting the first signal or the second signal through the ground wire and a path between the ground wire and the differential signal processing circuit.

PLC control method and apparatus

5-substituted difluoropiperidine compounds having a capacity to cross the blood-brain barrier are provided. The compound has the structural formula represented by formula (I): The 5-substituted difluoropiperidine compounds, derivatives and pharmaceutically acceptable salts thereof of the present invention have the ability to cross the blood-brain barrier and are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a vascular endothelial growth factor receptor 2 or SRC kinase family (FYN) and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, primary brain cancer (glioma), glioblastoma, cancer with meningeal metastases, Alzheimer's disease and central nervous system diseases, and the like.

5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability

A solar-powered aeration device for sludge turnover and planting includes a grow bed fixed on a floating body and floats on water. A bottom of the floating body is fixedly connected with an inner pipe; an outer pipe is sleeved outside the inner pipe. The outer pipe is nested in an air chamber; a bottom of the air chamber communicates and is fixedly connected with a water inlet pipe; the water inlet pipe laterally communicates with a suction tube. An aeration ring is fixedly arranged at a bottom of the outer pipe, and the aeration tube has an air outlet pipe in communication with the outside. A movable foot is rotationally provided at a tail end of the suction tube, and the movable foot adapts to surface fluctuations to swing in a range limited by an angle limiter.

Solar-powered aeration device for sludge turnover and planting and method

The present disclosure discloses substituted quinazoline compounds having a capacity to cross the blood-brain barrier. The compound has the structural formula represented by formula (I):  The quinazoline compounds, derivatives and pharmaceutically acceptable salts thereof of the present disclosure have the ability to cross the blood-brain barrier and are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a epidermal growth factor receptor and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, and neuroprotective diseases, and the like.

Substituted quinazoline compound having blood-brain barrier penetration capability

Growing community of inventors

Shanghai, China

Wei Zhong